There are not any upcoming events at the moment.
Please check soon for new updates.
[caption id="attachment_5930" align="alignnone" width="309"] Watch YouTube Webinar Recording[/caption]
Speakers
Liam Degnan – Senior Solutions Engineer @ Compliancy Group
Jim Potter – Executive Director @ CHC – Moderator
[caption id="attachment_5889" align="alignnone" width="721"] Watch Webinar YouTube Recording[/caption]
Speakers
Suzanna Boyle – Regulatory Council, Office of Medical Policy, OPDP @ U.S. Food and Drug Administration
James Potter – Executive Director @ CHC
FDA Education ResourcesSpeakers
Alison Pepper – EVP, Government Relations & Sustainability @ 4A’s – Moderator
Amanda Anderson – VP, Government Relations @ 4A’s
Michael Signorelli – Partner @ Venable LLP
Speakers
Elisa Jillson – Senior Attorney @ FTC
James Potter – Executive Director @ CHC
FTC Education ResourcesModerator
Jay Carter – CHC Board Chair /EVP Business Development @ AblesonTaylor
Speakers
James Potter – Executive Director @ CHC
Amanda Anderson – VP Government Relations @ 4A's
Michael Signorelli – Partner @ Venable LLP
Download the guidance: U.S. State Privacy Laws: What Agencies Need to Know – that focuses on the obligations these laws may impose upon agencies related to the personal information agencies collect and process, both on behalf of clients and for their own purposes.At the end of 2022, the Federal Trade Commission (FTC) released its Health Products Compliance Guidance—a blanket overhaul of the 1998 Guidance, Dietary Supplements: An Advertising Guide for Industry. The 2022 Guidance expands its scope to guide advertising practices for “any health-related product,” including dietary supplements, foods, over-the-counter (OTC) drugs, homeopathic products, devices, health equipment, diagnostic tests, and health-related apps” attempts to “correct misunderstandings” and “urban myths” that have circulated about past FTC substantiation standards. Separately, the Federal Drug Administration (FDA) finalized its Drug Products Labeled as Homeopathic guidance document, which explains FDA’s risk-based approach to prioritizing enforcement action for homeopathic drugs that FDA considers to be illegally marketed.
Speaker
Claudia Lewis, Partner @ Venable LLP
Nearly a year into the Biden administration, Dr. Robert Califf has been nominated to return as FDA Commissioner – amidst a continuing pandemic and criticism of recent FDA decisions and messaging. What’s next for the FDA under Dr. Califf’s leadership?
Speaker
Nancy Bradish Myers – President @ Catalyst Healthcare Consulting
Concern is building in Washington over misuse of personal data and risks to privacy. Meanwhile, Virginia just followed California in enacting comprehensive data privacy regulation, and other states are considering their own laws, forcing businesses to deal with different rules in different states.
Speaker
Alison Pepper – EVP Government Relations @ 4As